Technology Licensing opportunities

Available technologies

Clear search
Complement Factor H Knock Out Mouse Model

Disease model for research into conditions involving complement factor H

Zebrafish model for cardiac arrhythmia

POPDC1S191F zebrafish mutant

“Right-first-time” manufacturing set-up of MOFs

Accurate simulation of set-up parameters for the manufacturing of Micro-structured Optical Fibres (MOFs) enable significant cost reduction

Centrifugal Compressor Inlet Duct Device for Improved Flow Range

Innovative compressor inlet invention to increase compressor flow range with the use of an inlet duct that pre-swirls the inlet flow of the turbocharger compressor

An Asymmetric Double-Entry Turbine for Better Exhaust Gas Recirculation

Increased exhaust gas recirculation, average turbine efficiency and brake specific fuel consumption.

Bio-inspired flying drones for monitoring, maintenance and repair

On-board 3D printing, spider-like string dispensing and perching, multifunctional legs and origami bumpers.

The Benzodiazepine withdrawal symptom questionnaire (BWSQ)

A well-established, validated and widely-used self-assessment scoring system used in a number of clinical trials involving benzodiazepines.

Hybrid Powertrains

Imperial College London Engineers have developed innovative driveline technology in novel series and parallel arrangements, reducing complexity, weight and volume and providing approx. 40% cost savings in the powetrain.

LDEye Outpatient

LDEye Outpatient is an integrated solution for Non Alcoholic Fatty Liver Disease (NAFLD) patients consisting of:

1. A smart mobile application for coaching and monitoring patients' diet and exercise during their daily activities at home

2. A cloud-based web platform for the management of patients by doctors and dietitians with the capability of direct communication and the storage/analysis of data

Novel platform for vaccine development using modified Viral-like Particles (VLPs)

A novel platform for production of Viral-like Particles (VLPs) used as a single vaccine against a range of viruses, including HIV, HPV, or Ebola. The invention combines two technical innovations; core platform to generate non-infectious VLPs based on the modification of Mumps or Parainfluenza 5 viruses, and a ‘pseudotyping’ technology to incorporate viral glycoproteins of choice on the surface of VLPs. As a proof of concept, the platform was used in development of modified VLPs against HIV. When used as a vaccine, VLPs boosted the production of anti-HIV antibodies better than the native virus.

Subscribe for Licensing Opportunities updates
Keep up to date with new technologies and licensing opportunities coming out of Imperial College London